Health Care • Medical Specialities
$8.06 ▼ -0.12
(-1.47%)
MKT CAP: $1.67B • VOL: 13.59M
52W L $6 52W H $25
ALHC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.95B | $2.70B | $1.80B |
| YoY Revenue Growth % | +46.1% | +50.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $14.8M | -$101.6M | -$127.8M |
| Operating Margin % | 0.4% | -3.8% | -7.1% |
| Net Income (GAAP) | -$724.0K | -$128.0M | -$148.0M |
| EBITDA (Normalized) | $36.2M | -$68.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $139.9M | $34.8M | -$59.2M |
| Capital Expenditures (CapEx) | $26.8M | $41.4M | — |
| Free Cash Flow (FCF) | $113.1M | -$6.6M | -$59.2M |
| FCF Margin % | 2.9% | -0.2% | -3.3% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $575.8M | $432.9M | — |
| Total Debt (Short + Long Term) | $323.2M | $321.4M | — |
| Total Stockholders' Equity | $179.3M | $99.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALHC.